Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
05 2021
Historique:
received: 22 12 2020
accepted: 14 04 2021
revised: 20 05 2021
pubmed: 7 5 2021
medline: 26 8 2021
entrez: 6 5 2021
Statut: epublish

Résumé

Adherence to and completion of tuberculosis (TB) treatment remain problematic in many high-burden countries. 99DOTS is a low-cost digital adherence technology that could increase TB treatment completion. We conducted a pragmatic stepped-wedge cluster-randomized trial including all adults treated for drug-susceptible pulmonary TB at 18 health facilities across Uganda over 8 months (1 December 2018-31 July 2019). Facilities were randomized to switch from routine (control period) to 99DOTS-based (intervention period) TB treatment supervision in consecutive months. Patients were allocated to the control or intervention period based on which facility they attended and their treatment start date. Health facility staff and patients were not blinded to the intervention. The primary outcome was TB treatment completion. Due to the pragmatic nature of the trial, the primary analysis was done according to intention-to-treat (ITT) and per protocol (PP) principles. This trial is registered with the Pan African Clinical Trials Registry (PACTR201808609844917). Of 1,913 eligible patients at the 18 health facilities (1,022 and 891 during the control and intervention periods, respectively), 38.0% were women, mean (SD) age was 39.4 (14.4) years, 46.8% were HIV-infected, and most (91.4%) had newly diagnosed TB. In total, 463 (52.0%) patients were enrolled on 99DOTS during the intervention period. In the ITT analysis, the odds of treatment success were similar in the intervention and control periods (adjusted odds ratio [aOR] 1.04, 95% CI 0.68-1.58, p = 0.87). The odds of treatment success did not increase in the intervention period for either men (aOR 1.24, 95% CI 0.73-2.10) or women (aOR 0.67, 95% CI 0.35-1.29), or for either patients with HIV infection (aOR 1.51, 95% CI 0.81-2.85) or without HIV infection (aOR 0.78, 95% CI 0.46-1.32). In the PP analysis, the 99DOTS-based intervention increased the odds of treatment success (aOR 2.89, 95% CI 1.57-5.33, p = 0.001). The odds of completing the intensive phase of treatment and the odds of not being lost to follow-up were similarly improved in PP but not ITT analyses. Study limitations include the likelihood of selection bias in the PP analysis, inability to verify medication dosing in either arm, and incomplete implementation of some components of the intervention. 99DOTS-based treatment supervision did not improve treatment outcomes in the overall study population. However, similar treatment outcomes were achieved during the control and intervention periods, and those patients enrolled on 99DOTS achieved high treatment completion. 99DOTS-based treatment supervision could be a viable alternative to directly observed therapy for a substantial proportion of patients with TB. Pan-African Clinical Trials Registry (PACTR201808609844917).

Sections du résumé

BACKGROUND
Adherence to and completion of tuberculosis (TB) treatment remain problematic in many high-burden countries. 99DOTS is a low-cost digital adherence technology that could increase TB treatment completion.
METHODS AND FINDINGS
We conducted a pragmatic stepped-wedge cluster-randomized trial including all adults treated for drug-susceptible pulmonary TB at 18 health facilities across Uganda over 8 months (1 December 2018-31 July 2019). Facilities were randomized to switch from routine (control period) to 99DOTS-based (intervention period) TB treatment supervision in consecutive months. Patients were allocated to the control or intervention period based on which facility they attended and their treatment start date. Health facility staff and patients were not blinded to the intervention. The primary outcome was TB treatment completion. Due to the pragmatic nature of the trial, the primary analysis was done according to intention-to-treat (ITT) and per protocol (PP) principles. This trial is registered with the Pan African Clinical Trials Registry (PACTR201808609844917). Of 1,913 eligible patients at the 18 health facilities (1,022 and 891 during the control and intervention periods, respectively), 38.0% were women, mean (SD) age was 39.4 (14.4) years, 46.8% were HIV-infected, and most (91.4%) had newly diagnosed TB. In total, 463 (52.0%) patients were enrolled on 99DOTS during the intervention period. In the ITT analysis, the odds of treatment success were similar in the intervention and control periods (adjusted odds ratio [aOR] 1.04, 95% CI 0.68-1.58, p = 0.87). The odds of treatment success did not increase in the intervention period for either men (aOR 1.24, 95% CI 0.73-2.10) or women (aOR 0.67, 95% CI 0.35-1.29), or for either patients with HIV infection (aOR 1.51, 95% CI 0.81-2.85) or without HIV infection (aOR 0.78, 95% CI 0.46-1.32). In the PP analysis, the 99DOTS-based intervention increased the odds of treatment success (aOR 2.89, 95% CI 1.57-5.33, p = 0.001). The odds of completing the intensive phase of treatment and the odds of not being lost to follow-up were similarly improved in PP but not ITT analyses. Study limitations include the likelihood of selection bias in the PP analysis, inability to verify medication dosing in either arm, and incomplete implementation of some components of the intervention.
CONCLUSIONS
99DOTS-based treatment supervision did not improve treatment outcomes in the overall study population. However, similar treatment outcomes were achieved during the control and intervention periods, and those patients enrolled on 99DOTS achieved high treatment completion. 99DOTS-based treatment supervision could be a viable alternative to directly observed therapy for a substantial proportion of patients with TB.
TRIAL REGISTRATION
Pan-African Clinical Trials Registry (PACTR201808609844917).

Identifiants

pubmed: 33956802
doi: 10.1371/journal.pmed.1003628
pii: PMEDICINE-D-20-06186
pmc: PMC8136841
doi:

Substances chimiques

Antitubercular Agents 0

Banques de données

PACTR
['PACTR201808609844917']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003628

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: AS is owner and consultant for the human-centered design consultancy, The Empathy Studio, LLC. DP is a human-centered design consultant for The Empathy Studio, LLC. The other authors have declared that no competing interests exist.

Références

J Adv Nurs. 2007 Feb;57(3):227-43
pubmed: 17233644
N Engl J Med. 2019 Sep 5;381(10):986-987
pubmed: 31483974
Clin Infect Dis. 2020 Dec 3;71(9):e513-e516
pubmed: 32221550
JMIR Form Res. 2020 Dec 8;4(12):e19270
pubmed: 33289494
Lancet. 2019 Mar 23;393(10177):1216-1224
pubmed: 30799062
BMC Infect Dis. 2016 Oct 4;16(1):537
pubmed: 27716104
Glob Health Action. 2019;12(1):1568826
pubmed: 30712507
Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1112-1115
pubmed: 33126949
PLoS Med. 2019 Oct 4;16(10):e1002891
pubmed: 31584944
JMIR Mhealth Uhealth. 2020 Jul 31;8(7):e16634
pubmed: 32735220
Cochrane Database Syst Rev. 2015 May 29;(5):CD003343
pubmed: 26022367
PLoS Med. 2015 Sep 15;12(9):e1001877
pubmed: 26372602
J Clin Tuberc Other Mycobact Dis. 2020 Sep 12;21:100184
pubmed: 33204851
BMJ Open. 2020 Nov 27;10(11):e039895
pubmed: 33247012
East Afr Med J. 2005 Jul;82(7):337-42
pubmed: 16167705
PLoS Med. 2015 Sep 15;12(9):e1001876
pubmed: 26372470

Auteurs

Adithya Cattamanchi (A)

Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

Rebecca Crowder (R)

Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.

Alex Kityamuwesi (A)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

Noah Kiwanuka (N)

Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.

Maureen Lamunu (M)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

Catherine Namale (C)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

Lynn Kunihira Tinka (LK)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

Agnes Sanyu Nakate (AS)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

Joseph Ggita (J)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

Patricia Turimumahoro (P)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

Diana Babirye (D)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

Denis Oyuku (D)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

Christopher Berger (C)

Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.

Austin Tucker (A)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

Devika Patel (D)

The Better Lab, Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.

Amanda Sammann (A)

The Better Lab, Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.

Stavia Turyahabwe (S)

National Tuberculosis and Leprosy Program, Uganda Ministry of Health, Kampala, Uganda.

David Dowdy (D)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

Achilles Katamba (A)

Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.
Clinical Epidemiology and Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH